COTI-2
Axon 2841
CAS [1039455-84-9]
MF C19H22N6SMW 366.48
- Purity:99%
- Soluble in 0.1N HCl(aq) and DMSO
Description
COTI-2 is an anti-cancer drug which appears to act both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. Proposed to cause cancer cell death via apoptosis. COTI-2 exhibits potent anti-proliferative activity against a wide variety of human cancer cell lines in vitro (at nanomolar concentrations) and against human tumor xenografts.
KEYWORDS: COTI-2 | supplier | p53 activator | COTI2 | COTI 2 | CAS [1039455-84-9] | DNA-RNA | p53 | Activator | Transcription Factors
| KY Salim et al. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget. 2016 Jul 5;7(27):41363-41379. |
| MJ Duffy et al. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017 Sep;83:258-265. |
| S Maleki Vareki et al. Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS One. 2018 Jan 24;13(1):e0191766. |
- Certificate of Analysis
- Material Safety Data Sheet
Chemical name
N"-(6,7-Dihydroquinolin-8(5H)-ylidene)-4-(pyridin-2-yl)piperazine-1-carbothiohydrazide
Parent CAS No.
[1039455-84-9]
Axon Medchem的业务之一，是独有的Axon Ligands配体库，在世界范围内，被认为是药物研发的标准。这其中，针对850余种生物靶标（包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等），Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库，Axon Medchem还是欧洲著名的CRO公司，主要针对生物活性分子和药物类似分子展开合成及协议开发工作，在过去的10年中，Axon Medchem已经发现了多种潜在药物分子，并在生物医药界享有一定的声誉。
暂无问答
本网站将在规定时间内给予删除等相关处理。
